InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Rhea-AI Summary

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days.

The company has been granted an initial 180-day period until January 7, 2026, to regain compliance. If unsuccessful, InflaRx may consider transferring from Nasdaq Global Select Market to Nasdaq Capital Market, which could provide an additional 180 days until July 6, 2026, subject to meeting other listing requirements.

InflaRx develops anti-C5a and anti-C5a receptor technologies, including vilobelimab, an intravenous antibody, and INF904, an oral small molecule inhibitor.

Positive

• Company has 180 days initial compliance period to address the deficiency
• Option to potentially extend compliance period by additional 180 days through Nasdaq Capital Market transfer
• Trading continues unaffected in immediate term

Negative

• Stock price has traded below $1.00 for 30 consecutive business days
• Risk of potential delisting from Nasdaq if compliance is not achieved
• No guarantee of eligibility for additional compliance period if needed

Insights

Securities Compliance Expert

InflaRx faces potential Nasdaq delisting risk with 180 days to regain $1 minimum bid compliance or transfer to Nasdaq Capital Market.

InflaRx has received a Nasdaq deficiency notice for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days. This notice activates a standard regulatory procedure that gives the company until January 7, 2026 (180 calendar days) to regain compliance with the Minimum Bid Price Rule. The immediate good news for investors is that this notice has no immediate effect on the company's listing status or the trading of its shares.

If InflaRx fails to meet the minimum bid requirement within the initial compliance period, the company does have a potential second option: transferring from the Nasdaq Global Select Market to the Nasdaq Capital Market. This would provide an additional 180 days (until July 6, 2026) to regain compliance, though eligibility for this extension isn't guaranteed and would require meeting other listing criteria such as sufficient market value of publicly held shares.

This type of deficiency notice is a relatively common occurrence for biotech companies with depressed share prices. The company has several potential remedies available including implementing a reverse stock split, which would mathematically increase the share price without changing the company's underlying value. For a clinical-stage biopharmaceutical company like InflaRx, maintaining Nasdaq listing is crucial for capital raising capabilities, liquidity, and institutional investor access as they continue developing their complement-targeting therapeutics like vilobelimab and INF904.

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 7, 2026, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until July 6, 2026, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.

The Notice has no immediate effect on the listing or trading of the Company’s common shares. The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

Why did InflaRx (IFRX) receive a Nasdaq deficiency notice in July 2025?

InflaRx received the notice because its stock price closed below the minimum requirement of $1.00 per share for 30 consecutive business days, violating Nasdaq's minimum bid price requirement.

What is the deadline for InflaRx (IFRX) to regain Nasdaq compliance?

InflaRx has until January 7, 2026 (180 days) to regain compliance, with potential extension until July 6, 2026 if transferred to Nasdaq Capital Market.

What happens if InflaRx (IFRX) fails to meet Nasdaq's minimum bid requirement?

If InflaRx fails to regain compliance, it may face delisting from Nasdaq Global Select Market, though it could potentially transfer to Nasdaq Capital Market if eligible.

What are InflaRx's main drug candidates in development?

InflaRx's main candidates are vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule inhibitor of C5a-induced signaling.

How can InflaRx regain Nasdaq compliance?

To regain compliance, InflaRx's stock must maintain a closing bid price of $1.00 or higher for at least 10 consecutive business days during the compliance period.